News Related to Inflammatory Bowel Disease

Related coverage linked through entity extraction aliases.

Subcutaneous Infliximab Recaptures Disease Control After Treatment Interruption

Feb 16, 2026

New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.

AbbVie Reports Record Sales and Earnings Beat, Advances Clinical Pipeline

Feb 12, 2026

AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.